Rejuveron is a “hub and spoke” biotechnology company combating age-related diseases.

Rejuveron has built a diversified portfolio, acquired or developed internally, with the potential to not only address age-related diseases with high unmet need, but address the underlying hallmarks of aging. This is exemplified by Endogena, a clinical stage company pursuing advanced retinitis pigmentosa (the most common genetic form of retinal degeneration) via a novel rejuvenative mechanism that could be expanded into other retinopathies, and Rejuvenate Biomed, a clinical stage company developing a drug for acute and age-related sarcopenia (muscle wasting). Beyond these two most advanced assets, Rejuveron has also targeted oncology and cellular senescence, telomeric syndromes, and vascular dysregulation, specifically in vascular dementia and other neurological conditions.